Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

Wang Z, Grosskurth SE, Cheung T, Petteruti P, Zhang J, Wang X, Wang W, Gharahdaghi F, Wu J, Su N, Howard RT, Mayo M, Widzowski D, Scott DA, Johannes JW, Lamb ML, Lawson D, Dry JR, Lyne PD, Tate EW, Zinda M, Mikule K, Fawell SE, Reimer C, Chen H.

Cancer Res. 2018 Dec 1;78(23):6691-6702. doi: 10.1158/0008-5472.CAN-18-1362. Epub 2018 Oct 8.

PMID:
30297535
2.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.

Poon E, Mullins S, Watkins A, Williams GS, Koopmann JO, Di Genova G, Cumberbatch M, Veldman-Jones M, Grosskurth SE, Sah V, Schuller A, Reimer C, Dovedi SJ, Smith PD, Stewart R, Wilkinson RW.

J Immunother Cancer. 2017 Aug 15;5(1):63. doi: 10.1186/s40425-017-0268-8.

3.

AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.

Scarborough HA, Helfrich BA, Casás-Selves M, Schuller AG, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J.

Clin Cancer Res. 2017 Mar 15;23(6):1531-1541. doi: 10.1158/1078-0432.CCR-16-1179. Epub 2016 Sep 23.

4.

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.

Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF.

Oncotarget. 2016 Feb 23;7(8):9163-74. doi: 10.18632/oncotarget.7036.

5.

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, Howard T, Ioannidis S, Kazmirski S, Lamb ML, Larsen NA, Lyne PD, Mikule K, Ogoe C, Peng B, Petteruti P, Read JA, Su N, Sylvester M, Throner S, Wang W, Wang X, Wu J, Ye Q, Yu Y, Zheng X, Scott DA.

Bioorg Med Chem Lett. 2015 Dec 15;25(24):5743-7. doi: 10.1016/j.bmcl.2015.10.079. Epub 2015 Oct 27.

PMID:
26546219
6.

Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.

Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM.

Oncotarget. 2015 Feb 10;6(4):2407-20.

7.

PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.

Kirschner AN, Wang J, van der Meer R, Anderson PD, Franco-Coronel OE, Kushner MH, Everett JH, Hameed O, Keeton EK, Ahdesmaki M, Grosskurth SE, Huszar D, Abdulkadir SA.

J Natl Cancer Inst. 2014 Dec 13;107(2). pii: dju407. doi: 10.1093/jnci/dju407. Print 2015 Feb.

8.

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF.

Oncotarget. 2014 Jul 15;5(13):4990-5001.

9.

Silencing of enzymes involved in ceramide biosynthesis causes distinct global alterations of lipid homeostasis and gene expression.

Ruangsiriluk W, Grosskurth SE, Ziemek D, Kuhn M, des Etages SG, Francone OL.

J Lipid Res. 2012 Aug;53(8):1459-71. doi: 10.1194/jlr.M020941. Epub 2012 May 23.

10.

Emergence of Xin demarcates a key innovation in heart evolution.

Grosskurth SE, Bhattacharya D, Wang Q, Lin JJ.

PLoS One. 2008 Aug 6;3(8):e2857. doi: 10.1371/journal.pone.0002857.

11.

Characterization of cis-regulatory elements and transcription factor binding: gel mobility shift assay.

Lin JJ, Grosskurth SE, Harlan SM, Gustafson-Wagner EA, Wang Q.

Methods Mol Biol. 2007;366:183-201.

Supplemental Content

Loading ...
Support Center